Extract
Nontuberculous mycobacteria (NTM) are environmental pathogens causing disease in humans; however, not everyone exposed develops disease [1]. Those with underlying pulmonary diseases, persons over 60 years old, and women have an increased risk for nontuberculous mycobacterial pulmonary disease (NTM-PD) [1, 2]. Bronchiectasis is a lung condition characterised by chronic airway dilation and inflammation resulting in impaired mucus clearance and associated with NTM-PD [1–3]. Both NTM-PD and bronchiectasis are increasing in incidence in the U.S [2, 3]. Although patients with bronchiectasis are at increased risk of acquiring NTM-PD [1, 2], the incidence of NTM-PD in these patients is not well described. Previous U.S. Medicare data estimated those with bronchiectasis were 50 to 75-fold more likely to have a diagnosis of NTM-PD than those without bronchiectasis [4]. The objective of this analysis was to estimate the incidence of NTM-PD among U.S. Medicare enrollees newly diagnosed with bronchiectasis over the age of 65.
Abstract
We estimated the incidence of NTM-PD among U.S. Medicare beneficiaries newly diagnosed with bronchiectasis between 2006 and 2014. Overall incidence of NTM-PD was found to be as high as 1950 per 100,000 person-years.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of Interest: Kevin Winthrop reports grants from Insmed, Inc, AN2 Therapeutics, Paratek Pharmaceuticals, Redhill Biopharma; consulting fees from Insmed, Inc, AN2 Therapeutics, Paratek Pharmaceuticals, Redhill Biopharma, Spero Therapeutics; outside the submitted work. Emily Henkle reports consulting fees from and participation on an advisory board for AN2 Therapeutics; outside the submitted work. All other authors have nothing to disclose.
- Received January 4, 2022.
- Accepted March 17, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
